GO
Loading...

Teva Pharmaceutical Industries Ltd

More

  • NuPathe gets takeover offer from Israel's Teva Wednesday, 8 Jan 2014 | 8:04 AM ET

    Jan 8- NuPathe Inc said it received a buyout offer from Israel's Teva Pharmaceutical Industries Ltd for $114 million plus milestone payments related to NuPathe's Zecuity migraine treatment.

  • *FDA asks for more clinical trials on Lemtrada. The FDA also demanded Sanofi carry out further clinical trials using different designs and methods prior to approval, Sanofi said.

  • US regulators reject Sanofi's MS treatment Lemtrada Monday, 30 Dec 2013 | 7:23 AM ET

    Sanofi's Lemtrada multiple sclerosis treatment has failed to win approval from U.S. regulators, dealing a setback to a drug which was at the heart of the French drugmaker's $20 billion takeover of biotech firm Genzyme.

  • Midday movers: Twitter, Textron, Sprint & more Friday, 27 Dec 2013 | 12:00 PM ET

    Take a look at some of Friday's midday movers: Twitter, Textron, Sprint

  • Early movers: TWTR, TSLA, DDD, UPS, ANIP & more Friday, 27 Dec 2013 | 7:51 AM ET

    Some of the names on the move ahead of the open.

  • Jim Cramer often advocates viewing a sell-off as opportunity. Often, but not always.

  • UPDATE 1-Pfizer will allow Teva to sell generic Viagra Tuesday, 17 Dec 2013 | 12:53 PM ET

    Dec 17- Pfizer Inc on Tuesday said it would allow Teva Pharmaceutical Industries to sell generic forms of its Viagra anti-impotence treatment in the United States beginning in late 2017, in a settlement of longstanding patent litigation between the two drugmakers.

  • Pfizer will allow Teva to sell generic Viagra Tuesday, 17 Dec 2013 | 12:22 PM ET

    Dec 17- Pfizer Inc on Tuesday said it would allow Teva Pharmaceutical Industries to sell generic forms of its Viagra anti-impotence treatment in the United States beginning in late 2017, in a settlement of longstanding patent litigation between the two drugmakers.

  • FACTBOX-Valeant's deal machine stays in overdrive Monday, 16 Dec 2013 | 11:51 AM ET

    Dec 16- Valeant Pharmaceuticals International Inc, which agreed on Monday to buy Solta Medical Inc, is one of Canada's fastest-rising stocks.

  • FDA approves generics of Lilly antidepressant Cymbalta Wednesday, 11 Dec 2013 | 4:01 PM ET

    The FDA said it approved cheaper versions of the drug, known chemically as duloxetine, in a variety of strengths for sale by several generic drugmakers, including Teva Pharmaceutical Industries Ltd, Aurobindo Pharma Ltd, Dr. Reddy's Laboratories Ltd, Lupin Ltd, Sun Pharmaceutical Industries and Torrent Pharmaceuticals Ltd..

  • TEL AVIV, Dec 8- Teva Pharmaceutical Industries, the world's biggest maker of generic drugs, estimates its pipeline of so-called new therapeutic entities could generate revenue of $1 billion to $1.5 billion by 2018..

  • WASHINGTON, Nov 13- A U.S. Supreme Court justice on Wednesday declined a request from Teva Pharmaceutical Industries for a stay of an appeals court ruling that would strip the company's $4 billion- a-year multiple sclerosis drug Copaxone of patent protection in 2014, rather than in 2015..

  • Oct 31- Valeant Pharmaceuticals International Inc, Canada's biggest publicly traded drugmaker, posted a quarterly net loss on Thursday after restructuring and impairment charges, and cut its full-year revenue outlook.

  • Midday movers: Infosys, Sprint, Telsa & more Wednesday, 30 Oct 2013 | 12:41 PM ET

    Take a look at some of Wednesday's midday movers:

  • INSIGHT-Is Israel pulling down the shutters for business? Wednesday, 30 Oct 2013 | 7:31 AM ET

    TEL AVIV, Oct xx- High-tech entrepreneur Eyal Waldman decided he had had enough of Israeli investors when they told him to choose between his titles of chairman and chief executive at the company he co-founded, Mellanox Technologies. "Mellanox is not an impulsive company. is something we were thinking of, that we saw build up.

  • TEL AVIV, Oct 30- Teva Pharmaceutical Industries, the world's largest generic drugmaker, said its chief executive Jeremy Levin was stepping down and finance chief Eyal Desheh would stand in on an interim basis, effective immediately.

  • Midday movers: JCPenney, CF Industries & more Monday, 28 Oct 2013 | 12:12 PM ET

    Take a look at some of Monday's midday movers:

  • JERUSALEM, Oct 28- Teva Pharmaceutical Industries and Chief Executive Jeremy Levin denied an Israeli media report that Levin was considering resigning due to a rift with the company's board of directors.

  • Channel 2 television quoted unnamed sources as saying there were strong differences of opinion between Levin and Chairman Phillip Frost over the implementation of Teva's new strategy.

  • GSK's China sales topple on bribery scandal Wednesday, 23 Oct 2013 | 7:38 AM ET

    GlaxoSmithKline's pharmaceutical and vaccine sales to China tumbled 61 percent in the third quarter, with the drugmaker hit by an ongoing bribery investigation.

Most Popular Video

Wednesday, 23 Apr 2014 | 11:30 AM ET

Saving for retirement is about to get a whole lot more complicated. CNBC's Allison Linn reports on the "new normal" that may mean those planning to retire in 20-25 years may have to get used to a slightly lower standard of living than in the pension heyday.

Wednesday, 23 Apr 2014 | 11:00 AM ET

An 11th person was arrested yesterday in connection with a Philadelphia area drug ring where police say high school and college students were the targets.

Wednesday, 23 Apr 2014 | 10:17 AM ET

Former Apple CEO John Sculley, discusses Apple innovation and if the DNA of Apple has changed under CEO Tim Cook. Sculley also weighs in on earnings expectations for the tech giant.